0
selected
-
1.
Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A, Buschmann, MM, Gilbert, JA
Clinical pharmacology and therapeutics. 2019;(2):317-328
Abstract
The human body, with 3.0 × 1013 cells and more than 3.8 × 1013 microorganisms, has nearly a one-to-one ratio of resident microbes to human cells. Initiatives like the Human Microbiome Project, American Gut, and Flemish Gut have identified associations between microbial taxa and human health. The study of interactions between microbiome and pharmaceutical agents, i.e., pharmacomicrobiomics, has revealed an instrumental role of the microbiome in modulating drug response that alters the therapeutic outcomes. In this review, we present our current comprehension of the relationship of the microbiome, host biology, and pharmaceutical agents such as cardiovascular drugs, analgesics, and chemotherapeutic agents to human disease and treatment outcomes. We also discuss the significance of studying diet-gene-drug interactions and further address the key challenges associated with pharmacomicrobiomics. Finally, we examine proposed models employing systems biology for the application of pharmacomicrobiomics and other -omics data, and provide approaches to elucidate microbiome-drug interactions to improve future translation to personalized medicine.
-
2.
Architectures and Mechanical Properties of Drugs and Complexes of Surface-Active Compounds at Air-Water and Oil-Water Interfaces.
Sarker, DK
Current drug discovery technologies. 2019;(1):11-29
Abstract
BACKGROUND Drugs can represent a multitude of compounds from proteins and peptides, such as growth hormones and insulin and on to simple organic molecules such as flurbiprofen, ibuprofen and lidocaine. Given the chemical nature of these compounds two features are always present. A portion or portions of the molecule that has little affinity for apolar surfaces and media and on the contrary a series of part or one large part that has considerable affinity for hydrophilic, polar or charged media and surfaces. A series of techniques are routinely used to probe the molecular interactions that can arise between components, such as the drug, a range of surface- active excipients and flavor compounds, for example terpenoids and the solvent or dispersion medium. RESULTS Fifty-eight papers were included in the review, a large number (16) being of theoretical nature and an equally large number (14) directly pertaining to medicine and pharmacy; alongside experimental data and phenomenological modelling. The review therefore simultaneously represents an amalgam of review article and research paper with routinely used or established (10) and well-reported methodologies (also included in the citations within the review). Experimental data included from various sources as diverse as foam micro-conductivity, interferometric measurements of surface adsorbates and laser fluorescence spectroscopy (FRAP) are used to indicate the complexity and utility of foams and surface soft matter structures for a range of purposes but specifically, here for encapsulation and incorporation of therapeutics actives (pharmaceutical molecules, vaccines and excipients used in medicaments). Techniques such as interfacial tensiometry, interfacial rheology (viscosity, elasticity and visco-elasticity) and nanoparticle particle size (hydrodynamic diameter) and charge measurements (zeta potential), in addition to atomic force and scanning electron microscopy have proven to be very useful in understanding how such elemental components combine, link or replace one another (competitive displacement). They have also proven to be both beneficial and worthwhile in the sense of quantifying the unseen actions and interplay of adsorbed molecules and the macroscopic effects, such as froth formation, creaming or sedimentation that can occur as a result of these interactions. CONCLUSION The disclosures and evaluations presented in this review confirm the importance of a theoretical understanding of a complex model of the molecular interactions, network and present a framework for the understanding of really very complex physical forms. Future therapeutic developers rely on an understanding of such complexity to garner a route to a more successful administration and formulation of a new generation of therapeutic delivery systems for use in medicine.
-
3.
The Role of the Phosphorus Atom in Drug Design.
Rodriguez, JB, Gallo-Rodriguez, C
ChemMedChem. 2019;(2):190-216
Abstract
Although the phosphorus atom is found in a variety of oxidation states, most of the phosphorus-containing molecules of pharmacological importance possess phosphorus in the form of phosphonate or phosphinate functional groups, or in a major oxidation state as a phosphate group. The most common occurrence of phosphorus in drugs is either in prodrugs or in compounds for which the phosphorus atom plays a role in the biological activity, such as in modified nucleotides, in metabolically stable analogues of metabolites bearing phosphate groups, and as bioisosteric analogues of carboxyl groups.
-
4.
Photocatalytic degradation of pharmaceutical micro-pollutants using ZnO.
Sabouni, R, Gomaa, H
Environmental science and pollution research international. 2019;(6):5372-5380
Abstract
This research paper presents the results of an experimental investigation of the degradation of three different contaminants including progesterone (PGS), ibuprofen (IBU), and naproxen (NAP) using ZnO as the photocatalyst and ultraviolet (UV) light as a source for catalysts activation. Two operating parameters, namely, catalyst loading and initial concentration of contaminants, were tested in a batch photocatalytic reactor. To demonstrate the large-scale applications, experiments were also conducted in a submerged membrane photocatalytic reactor. It has proven that ZnO photocatalyst degraded the three contaminants very efficiently under almost all the studied experimental conditions, with efficiency rates of 92.3, 94.5, and 98.7 % for PSG, IBU, and NAP, respectively. The photodegradation kinetics study was performed to calculate the reaction rate constant, which is found to follow pseudo-first order kinetics. The membrane photocatalytic reactor was efficient to remove pollutants and it is observed that the degradation rate increases with increasing the membrane oscillation frequency approaching that of the stirred reactor.
-
5.
A new gastro-intestinal mathematical model to study drug bioavailability.
Pompa, M, Capocelli, M, Piemonte, V
Medical engineering & physics. 2019;:106-114
Abstract
This work focuses on a new mathematical model which describes the gastro-intestinal absorption of drugs and the effect of food interactions on drugs bioavailability. The model structure consists of five compartments (stomach, duodenum, jejunum feeding, intestine and blood) simulated though different in-series reactors. All the enzymatic reactions taking place in the gastro-intestinal system are described through the Michaelis-Menten kinetic equations. The model has been tested for drug administration (paracetamol and ketoprofen) with and without the meal digestion. The model has been validated through pharmacokinetics curves obtained from in vivo tests (reported in the literature) and used to simulate the drug absorption dynamics in different conditions. The maximum blood concentration were 0.153 mmol L-1 and 0.0243 mmol L-1, respectively for paracetamol and ketoprofen. The time to reach the maximum concentration for the paracetamol and ketoprofen was around 55 min. In case of contemporary meal digestion, the maximum concentration of paracetamol in the blood was 0.100 mmol L-1 and 0.0135 mmol L-1 for ketoprofen; the time to reach the maximum concentration was 3 h and 45 min for paracetamol and 3 h and 35 min for ketoprofen. The drugs showed different pharmacokinetics, in agreement with the literature, during the digestion of food. To show the predictive capacity of the model, the simulations were also compared against additional experimental data (obtained from in vivo tests available in the literature) relative to ketoprofen administration with food.
-
6.
Interpreting non-linear drug diffusion data: Utilizing Korsmeyer-Peppas model to study drug release from liposomes.
Wu, IY, Bala, S, Škalko-Basnet, N, di Cagno, MP
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2019;:105026
Abstract
The aim of this work was to clarify the dynamics behind the influence of ionic strength on the changes in drug release from large unilamellar vesicles (LUVs). For this purpose, we have investigated the transport of two different model drugs (caffeine and hydrocortisone) formulated into liposomes through different types of barriers with different retention properties (regenerated cellulose and the newly introduced biomimetic barrier, Permeapad®). Drug release from liposomes was studied utilizing the standard Franz diffusion cells. LUV dispersions were exposed to the isotonic, hypotonic and hypertonic environment (difference of 300 mOsm/kg between the initial LUVs and the environment) and experimental data treated with both linear and non-linear (Korsmeyer-Peppas) regression models. To alter the rigidity of the liposomal membranes, cholesterol was introduced in the liposomal barriers (up to 25% w/w). Korsmeyer-Peppas model was proven to be suited to analyse experimental data throughout the experimental time frame, providing important additive information in comparison to standard linear approximation. The obtained results are highly relevant as they improve the interpretation of drug release kinetics from LUVs under osmotic stress. Moreover, the findings can be utilized in the development of liposomal formulations intended for nose-to-brain targeted drug delivery.
-
7.
Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.
Fuhr, U, Hsin, CH, Li, X, Jabrane, W, Sörgel, F
Annual review of pharmacology and toxicology. 2019;:507-536
Abstract
Pharmacokinetic parameters of selective probe substrates are used to quantify the activity of an individual pharmacokinetic process (PKP) and the effect of perpetrator drugs thereon in clinical drug-drug interaction (DDI) studies. For instance, oral caffeine is used to quantify hepatic CYP1A2 activity, and oral dagibatran etexilate for intestinal P-glycoprotein (P-gp) activity. However, no probe substrate depends exclusively on the PKP it is meant to quantify. Lack of selectivity for a given enzyme/transporter and expression of the respective enzyme/transporter at several sites in the human body are the main challenges. Thus, a detailed understanding of the role of individual PKPs for the pharmacokinetics of any probe substrate is essential to allocate the effect of a perpetrator drug to a specific PKP; this is a prerequisite for reliably informed pharmacokinetic models that will allow for the quantitative prediction of perpetrator effects on therapeutic drugs, also in respective patient populations not included in DDI studies.
-
8.
A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.
Ito, R, Umehara, K, Suzuki, S, Kitamura, K, Nunoya, KI, Yamaura, Y, Imawaka, H, Izumi, S, Wakayama, N, Komori, T, et al
Molecular pharmaceutics. 2019;(11):4461-4471
Abstract
Brain microvascular endothelial cells (BMEC), together with astrocytes and pericytes, form the blood-brain barrier (BBB) that strictly restricts drug penetration into the brain. Therefore, in central nervous system drug development, the establishment of an in vitro human BBB model for use in studies estimating the in vivo human BBB permeability of drug candidates has long been awaited. The current study developed and characterized a human immortalized cell-based BBB triculture model, termed the "hiBBB" model. To set up the hiBBB model, human immortalized BMEC (HBMEC/ci18) were cocultured with human immortalized astrocytes (HASTR/ci35) and brain pericytes (HBPC/ci37) in a transwell system. The trans-endothelial electrical resistance of the hiBBB model was 134.4 ± 5.5 (Ω × cm2), and the efflux ratios of rhodamine123 and dantrolene were 1.72 ± 0.11 and 1.72 ± 0.45, respectively, suggesting that the hiBBB model possesses essential cellular junction and efflux transporter functions. In BBB permeability assays, the mean value of the permeability coefficients (Pe) of BBB permeable compounds (propranolol, pyrilamine, memantine, and diphenhydramine) was 960 × 10-6 cm/s, which was clearly distinguishable from that of BBB nonpermeable compounds (sodium fluorescein and Lucifer yellow, 18 × 10-6 cm/s). Collectively, this study successfully developed the hiBBB model, which exhibits essential BBB functionality. Taking into consideration the high availability of the immortalized cells used in the hiBBB model, our results are expected to become an initial step toward the establishment of a useful human BBB model to investigate drug penetration into the human brain.
-
9.
Miniaturized shake-flask HPLC method for determination of distribution coefficient of drugs used in inflammatory bowel diseases.
Brusač, E, Jeličić, ML, Klarić, DA, Mornar, A
Acta pharmaceutica (Zagreb, Croatia). 2019;(4):649-660
Abstract
A new method for determination of distribution coefficient of drugs azathioprine, 6-mercaptopurine and 6-thioguanine and nutrient folic acid used in the treatment of inflammatory bowel disease based on a miniaturized shake-flask and HPLC/DAD was developed. Special attention was made to the most commonly reported problems in the measurement of distribution coefficients using a shake-flask method such as mixing technique, speed and time, the temperature of experiment, type of buffer and its pH as well as n-octanol/buffer phase ratio. The concentration of compounds in the buffer is determined by HPLC directly from shake flasks or conventional 2-mL vials. The developed method was fully validated according to ICH guidelines. Furthermore, experimental data were successfully compared with lipophilicity and human intestinal absorption calculated by the use of four different theoretical approaches. The method shows potential for high-throughput measurements of a large number of compounds.
-
10.
Effectiveness of pharmaceutical interventions for meibomian gland dysfunction: An evidence-based review of clinical trials.
Khoo, P, Ooi, KG, Watson, S
Clinical & experimental ophthalmology. 2019;(5):658-668
Abstract
Meibomian gland dysfunction is one of the most common ocular disorders encountered by ophthalmologists and is the leading cause of evaporative dry eye. The disease causes significant morbidity in the population such that patients seek treatment. Multiple clinical studies on pharmacological and mechanical interventions for the treatment of meibomian gland dysfunction have been evaluated. However, there is limited comparative clinical evidence for the effectiveness of these interventions. This review paper aims to report the clinical evidence for pharmaceutical interventions for meibomian gland dysfunction in order to guide clinicians in the management of the disease.